Navigation Links
Vical to Present at Cowen and Company Health Care Conference
Date:3/12/2008

BOSTON, March 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) announced today that the company will present an overview of its product development programs on Monday, March 17, at the 28th Annual Cowen and Company Health Care Conference (Boston -- March 17-20).

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vical to Present at BIO and BVGH Global Health Partnering Event
2. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
3. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
4. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
5. Vical Launches Redesigned Website
6. Vical Presentation at Military Pandemic Influenza Workshop
7. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
8. Vical to Present at Investor Conferences
9. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
10. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
11. Nventa updates progress of cervical dysplasia trial with new HspE7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... N.Y. , Dec. 2, 2016 More than ... (CSHL) 11th Double Helix Medals dinner ( DHMD ). The gala was ... New York City and honored ... their contributions, respectively, to health and medicine and the public ... Ali in 2006, the event has raised $40 million ...
(Date:12/2/2016)... Research and Markets has announced the addition of ... to their offering. ... , , An ... is anticipated. Nanotechnology will be applied at all stages of ... applications in clinical trials. Many of the assays based on ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... Computational Science Symposium (CSS) and the popularity of US Single Day Events (SDE) ... place in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... and biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control ... vendor-supported, portable online UHPLC, with robust, probe-based sampling. , Online liquid ...
Breaking Biology Technology:
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):